

# Delivering Greater Value

## A Biosimilar-First Approach for Stelara®



SlateRx has implemented a biosimilar-first strategy for ustekinumab (Stelara®) across our managed formularies. This shift prioritizes Wezlana™, an FDA-approved biosimilar, to help clients realize substantial savings while maintaining clinical excellence.

### Key Biosimilar Strategy Highlights

#### ➤ Clinically Driven and Cost-Conscious

- Wezlana™ is the preferred product
- Treatment based on safety, efficacy, financial value, and member impact
- Lowest net cost biosimilar option

#### ➤ Uninterrupted Patient Care

- Wezlana™ is interchangeable—no need for a new prescription
- Same strength and dosage as Stelara®
- Maintains therapeutic efficacy and cost-efficiency

#### ➤ Commitment to Safety, Efficacy, and Value

- Rigorous standards for clinical effectiveness and patient safety
- Wezlana™ is latex-free

#### ➤ High-Touch Clinical Oversight

- Prescriber engagement and patient support throughout formulary transition
- Protection against inappropriate use

#### ➤ Ongoing Market Basket Monitoring

- Continuously monitoring biosimilar competition and pricing to always pursue a lowest net cost strategy
- Delivering the best value aligned with plan sponsor goals

#### ➤ Manufacturer Copay Support

- Manufacturer copay assistance available up to \$10,000 per year
- Most members' out-of-pocket cost \$0



Our strategy reflects a core belief that affordability, efficacy, and access are not mutually exclusive. By using biosimilars that meet the FDA's high standards for safety and therapeutic equivalence, we're improving drug management and spend for our clients and members.



To learn how SlateRx's biosimilar-first strategy could benefit your plan, contact us at [inquiries@Slate-Rx.com](mailto:inquiries@Slate-Rx.com).